Inventor · disambiguated record
Jackie Sheng
Also filed as: SHENG JACKIE Z · SHENG JACKIE ZEQI · SHENG Jackie
28 granted patents·11 pending applications·95 citations·filing 2008–2025
95Inventor score
Top patents by PatentIndex Score
39 records- 0192US10537637B2Checkpoint regulator antagonistsGENSUN BIOPHARMA INC·Filed 2017·Granted Jan 21, 2020·5 cites·8 claims
- 0292US9862752B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2014·Granted Jan 9, 2018·16 cites·27 claims
- 0392US9714276B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2013·Granted Jul 25, 2017·17 cites·18 claims
- 0491US11518813B2Trispecific antagonistsGENSUN BIOPHARMA INC·Filed 2020·Granted Dec 6, 2022·2 cites·14 claims
- 0591US10851157B2Antagonists targeting the TGF-β pathwayGENSUN BIOPHARMA INC·Filed 2019·Granted Dec 1, 2020·5 cites·34 claims
- 0691US10647773B2Trispecific antagonistsGENSUN BIOPHARMA INC·Filed 2019·Granted May 12, 2020·4 cites·15 claims
- 0791US10336798B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2017·Granted Jul 2, 2019·9 cites·21 claims
- 0891US2025361306A1Antitumor immune checkpoint regulator antagonistsGENSUN BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 0990US10894814B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2017·Granted Jan 19, 2021·4 cites·25 claims
- 1089US11001635B2Antitumor antagonistsGENSUN BIOPHARMA INC·Filed 2019·Granted May 11, 2021·2 cites·4 claims
- 1188US11976133B2Bispecific T cell engagersGENSUN BIOPHARMA INC·Filed 2021·Granted May 7, 2024·2 cites·10 claims
- 1287US12404336B2Bispecific antagonist comprising a LAG-3 binding domainGENSUN BIOPHARMA INC·Filed 2023·Granted Sep 2, 2025·0 cites·20 claims
- 1386US11517623B2Anti-PD-1 antibodies, antigen-binding portions thereof and checkpoint regulator antogonists comprising the sameGENSUN BIOPHARMA INC·Filed 2019·Granted Dec 6, 2022·1 cites·17 claims
- 1484US11739131B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2019·Granted Aug 29, 2023·1 cites·6 claims
- 1584US8629250B2Hepcidin, hepcidin antagonists and methods of useSASU BARBRA·Filed 2008·Granted Jan 14, 2014·14 cites·15 claims
- 1684US2024368236A1Growth differentiation factor 15 (gdf-15) constructsAMGEN INC·Filed 2024·Application pending·0 cites
- 1782US12350333B2Checkpoint regulator antagonistsGENSUN BIOPHARMA INC·Filed 2022·Granted Jul 8, 2025·0 cites·16 claims
- 1882US10752664B2Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)XIONG YUMEI·Filed 2012·Granted Aug 25, 2020·4 cites·11 claims
- 1978US11945873B2Antitumor antagonistsGENSUN BIOPHARMA INC·Filed 2021·Granted Apr 2, 2024·0 cites·6 claims
- 2078US10894823B2Trispecific inhibitors for cancer treatmentGENSUN BIOPHARMA INC·Filed 2017·Granted Jan 19, 2021·1 cites·7 claims
- 2177US9175078B2Ferroportin antibodies and methods of useARVEDSON TARA·Filed 2009·Granted Nov 3, 2015·6 cites·53 claims
- 2275US11851493B2Trispecific antagonistsGENSUN BIOPHARMA INC·Filed 2020·Granted Dec 26, 2023·0 cites·20 claims
- 2374US11667716B2Bispecific antagonist comprising a LAG-3 binding domainGENSUN BIOPHARMA INC·Filed 2020·Granted Jun 6, 2023·0 cites·19 claims
- 2474US11078464B2High titer recombinant AAV vector production in adherent and suspension cellsAMGEN INC·Filed 2014·Granted Aug 3, 2021·2 cites·14 claims
- 2570US12486331B2Bispecific T cell engagersGENSUN BIOPHARMA MXY·Filed 2024·Granted Dec 2, 2025·0 cites·18 claims
- 2670US10597453B2Antitumor immune checkpoint regulator antagonistsGENSUN BIOPHARMA INC·Filed 2019·Granted Mar 24, 2020·0 cites·14 claims
- 2767US12018073B2Antagonists targeting the TGF-β pathwayGENSUN BIOPHARMA INC·Filed 2020·Granted Jun 25, 2024·0 cites·22 claims
- 2864US2025388703A1Multi-specific molecules and mentod of use and making thereofGENSUN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 2963US11834683B2High titer recombinant AAV vector production in adherent and suspension cellsAMGEN INC·Filed 2021·Granted Dec 5, 2023·0 cites·14 claims
- 3061US2025051444A1Multi-specific t cell engagers comprising lrrc15 antigen-binding domainSUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 3160US2021115123A1Trispecific inhibitors for cancer treatmentGENSUN BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 3260US2020325200A1Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)AMGEN INC·Filed 2020·Application pending·0 cites
- 3358US12060434B2Trispecific T cell engagersGENSUN BIOPHARMA INC·Filed 2021·Granted Aug 13, 2024·0 cites·4 claims
- 3458US2022389120A1Multispecific antagonistsGENSUN BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3556US2024279324A1Multispecific antagonistsGENSUN BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3654US2014286953A1Hepcidin, hepcidin antagonists and methods of useAMGEN INC·Filed 2013·Application pending·0 cites
- 3751US2013018176A1Methods of producing hybridomas and monoclonal antibodies and antibodies produced therebyAMGEN INC·Filed 2012·Application pending·0 cites
- 3846US9688759B2Ferroportin antibodies and methods of useAMGEN INC·Filed 2015·Granted Jun 27, 2017·0 cites·12 claims
- 3941US2014189893A1Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta klothoLI YANG·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jackie Sheng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →